Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy.

Autor: Keshari S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shavkunov AS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Miao Q; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saha A; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Minowa T; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Molgora M; Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA., Williams CD; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chaib M; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Highsmith AM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pineda JE; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alekseev S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Program of Biology, The University of Texas at San Antonio, San Antonio, TX, USA., Alspach E; Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA., Hu KH; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Colonna M; Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA., Pauken KE; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gubin MM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mgubin@mdanderson.org.

Publikováno v: Cell reports [Cell Rep] 2024 Oct 23; Vol. 43 (11), pp. 114875. Date of Electronic Publication: 2024 Oct 23.

BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy.

Autor: Salmon AJ; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shavkunov AS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Miao Q; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jarjour NN; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri., Keshari S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Esaulova E; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri., Williams CD; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ward JP; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., Highsmith AM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pineda JE; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Taneja R; Department of Physiology, Healthy Longevity Translation Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Edelson BT; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri., Gubin MM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2022 May 03; Vol. 10 (5), pp. 597-611.